Heyholder
‹ Activism Filings

ImmuneOncia Therapeutics, Inc. Q3 operating loss of KRW 9.1 billion with no revenue

ImmuneOncia Therapeutics, Inc.· Periodic Report

AI summary · Not investment advice

Immuneoncia had no sales in the third quarter and lost KRW 9.1 billion from its main business, versus a KRW 10.6 billion loss a year earlier.

Operating profit · 3 months

KRW -9.1 billion

Key facts

Revenue (3 months)
KRW 0
Net income (3 months)
KRW -8.1 billion
Period
Q3 (cumulative Jan 1, 2026 ~ Sep 30, 2026)
Revenue (prior-year 3 months)
KRW 0
Revenue (year to date)
KRW 0
Operating profit (prior-year 3 months)
KRW -10.6 billion
Operating profit (year to date)
KRW -19.2 billion
Net income (prior-year 3 months)
KRW -10.4 billion
Net income (year to date)
KRW -17.6 billion

Comments

No comments yet

Comments from shareholders will appear here.